In an earlier article, we discussed measures for identifying the cheapest oil companies and provided a ranked valuation list. Companies at the top of this list tend to eventually get bought out. Or they get analyst upgrades that send them soaring. Pinecrest, which was at the top of the list published three weeks ago, has jumped 40% since then. Twin Butte is up 12%, despite going ex-dividend.
Here are the current top five companies in the list:
CompanySymbolEV/BOEPD/NetbackPrice/NAVEV/DACFPinecrest(PNCGF.PK)53564%4.0XLightstream(LSTMF.PK)131753%4.5XNovus(NOVUF.PK)133290%4.1XZargon(ZARFF.PK)138664%5.6XTwin Butte(TBTEF.PK)155885%5.5XOf the larger companies, one that remains obstinately near the top of the list is Lightstream . Lightstream trades at 40% of its book value and a whopping 13.4% yield.
Top 10 Asian Stocks To Buy For 2015: NewLink Genetics Corp (NLNK)
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.
The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.
HyperAcute Cancer Immunotherapy Product Candidates
In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.
HyperAcute Cancer Immunotherapy Technology
The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.
IDO Pathway Inhibitor Product Candidate
The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.
Advisors' Opinion:- [By Jayson Derrick]
NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and ��athering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.��Shares fell 16.20 percent, closing at $31.60.
Best Cheapest Stocks To Own Right Now: Spectrum Rare Earths Ltd (SPX)
Spectrum Rare Earths Limited, formerly TUC Resources Ltd, is engaged in the exploration and evaluation of rare earths, uranium, base metals and gold mineral interests. On October 2, 2012, holds approximately 18,000 square kilometer of prospective land package across 44 tenements. During the fiscal year ended June 30, 2011, the Company is focuses on its Stromberg Heavy Rare Earth Project. The Company has 50, 100% owned tenements in the Northern Territory. Tenements within the Pine Creek Project consist of EL's 24884, 25224, 25228 and uranium rights on EL24906. Parts of EL24906 and EL24884 are located within the Rum Jungle Mineral Field. The Arnhem Project encompasses all the Company�� tenement holdings in the East Alligator River region within 150 kilometer of the high grade Narbalek uranium mine. The Litchfield Uranium Project consists of granted licenses EL25195 and EL25176 and license applications 25472, 25473 and 25221. Advisors' Opinion:- [By Lu Wang]
Almost $95 billion was poured into exchange-traded funds of American shares this year, while developing-nation ETFs saw withdrawals of $8.4 billion, according to data compiled by Bloomberg. The Standard & Poor�� 500 Index (SPX) trades at 16 times profit, 70 percent more than the MSCI Emerging Markets Index. A measure of historical price swings indicates the U.S. market is the calmest in more than six years compared with shares from China, Brazil, India and Russia.
- [By John Reese]
His back-testing found that focusing on stocks that rated highly in those areas would have produced a remarkable 30.8% return from 1988 through 2004, more than doubling the S&P 500's (SPX) 12.4% return during that period.
- [By Nick Taborek]
The Standard & Poor�� (SPX) 500 Index slipped 0.1 percent to 1,707.14 at 4 p.m. in New York. The Dow Jones Industrial Average lost 46.23 points, or 0.3 percent, to 15,612.13. About 4.6 billion shares changed hands on U.S. exchanges today, 27 percent below the three-month average.
- [By Adam Haigh]
Futures on the Standard & Poor�� 500 Index (SPX) rose 0.4 percent. Financial and energy shares tumbled yesterday, leading the S&P 500 to its largest drop in five weeks, as ADP Research Institute data showed U.S. companies boosted employment by 158,000 workers in March, less than the median forecast of 39 economists surveyed by Bloomberg who called for a 200,000 gain.
Best Cheapest Stocks To Own Right Now: WPX Energy Inc (WPX)
WPX Energy, Inc. (WPX Energy), incorporated on April 19, 2011, is an independent natural gas and oil exploration and production company engaged in the exploitation and development of long-life unconventional properties. The Company focuses on exploiting its natural gas reserve base and related NGLs in the Piceance Basin of the Rocky Mountain region, and on developing its positions in the Bakken Shale oil play in North Dakota and the Marcellus Shale natural gas play in Pennsylvania. Its other areas of domestic operations include the Powder River Basin in Wyoming and the San Juan Basin in the southwestern United States. In addition, it owns a 69% controlling ownership interest in Apco Oil and Gas International, Inc. (Apco), which holds oil and gas concessions in Argentina and Colombia. As of December 31, 2010, it had proved reserves of 4,473 Bcfe, 59% of which were proved developed reserves. Average daily production as of March 31, 2011 was 1,251 MMcfe/d.
Bakken Shale
The Company acquired 89,420 net acres in the Williston Basin in North Dakota that is prospective for oil in the Bakken Shale. It acquired all of this acreage in December 2010 through the acquisition of Dakota-3 E&P Company LLC. As of December 31, 2010, it had three rigs operating on the Bakken Shale acreage. Since acquiring this acreage, the Company has drilled 10 operated wells on the Bakken Shale properties; nine Middle Bakken formation wells and one Three Forks formation well. Six of these wells have been completed and connected to sales with initial 30 day production rates ranging from 750 Boe/d to 1,100 Boe/d.
Marcellus Shale
The Company�� 99,301 net acres in the Marcellus Shale were acquired through two key transactions and additional leasing activities. In July 2010, the Company acquired 42,000 net acres in Susquehanna County in northeastern Pennsylvania. As of December 31, 2010, the Company had five rigs operating in the Marcellus Shale.
Advisors' Opinion:- [By Sean Williams]
The final two big gainers didn't have any company specific news that sent them rocketing higher today, but instead, relied on a very big rally in natural gas for their ascent. Following yesterday's data, which showed a 94-billion cubic foot reduction in natural gas inventories, spot natural gas prices jumped higher by better than 4%. That was enough of a propellant to send natural gas-heavy independent E&P companies like Cabot Oil & Gas (NYSE: COG ) and WPX Energy (NYSE: WPX ) �higher by 5.1% and 5.2%, respectively.
- [By MARKETWATCH]
SAN FRANCISCO (MarketWatch) -- Wall Street hedge-fund investor David Einhorn was active in the last quarter of 2013, taking new stakes in technology and energy companies, while trimming existing holdings in insurer Aetna (AET) , NCR Corp (NCR) and WPX Energy (WPX) , according to an SEC filing Friday. Einhorn's Greenlight Capital picked up stakes in Anadarko Petroleum (APC) , BP (BP) , McDermott Intl. (MDR) , Micron Technolgy (MU) and Take-Two Interactive (TTWO) , according to the latest 13F filing. He trimmed stakes in Aetna, Einstein Noah (BAGL) and WPX Energy, according to the filing.
Best Cheapest Stocks To Own Right Now: Changyou.com Limited(CYOU)
Changyou.com Limited develops and operates online games in the People?s Republic of China. It involves in the development, operation, and licensing of massively multi-player online role-playing games (MMORPGs), which are interactive online games that might be played simultaneously by various game players. The company operates seven MMORPGs that include its in house developed Tian Long Ba Bu; and licensed Blade Online, Blade Hero 2, Da Hua Shui Hu, Zhong Hua Ying Xiong, Immortal Faith, and San Jie Qi Yuan. As of December 31, 2010, Changyou?s games in China had approximately 111.4 million aggregate registered accounts; 1.0 million aggregate peak concurrent users; and 2.7 million aggregate active paying accounts. The company was founded in 2003 and is based in Beijing, the People?s Republic of China. Changyou.com Limited is a subsidiary of Sohu.com Inc.
Advisors' Opinion:- [By Seth Jayson]
Changyou.com (Nasdaq: CYOU ) is expected to report Q2 earnings on July 29. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Changyou.com's revenues will increase 24.3% and EPS will expand 1.5%.
Best Cheapest Stocks To Own Right Now: 22nd Century Group Inc (XXII)
22nd Century Group, Inc. (22nd Century Group), incorporated on September 12, 2005, is a holding company. The Company�� wholly owned subsidiary, 22nd Century Limited, LLC (22nd Century Ltd), which is a plant biotechnology company. The Company�� products include X-22 Smoking Cessation Aid, Modified Risk Cigarettes, BRAND A Cigarettes and BRAND B Cigarettes. On January 25, 2011, 22nd Century Limited, LLC (22nd Century Ltd) completed a reverse merger transaction (the Merger) with 22nd Century Group, and as a result, 22nd Century Ltd became a wholly owned subsidiary of 22nd Century Group, which continues to operate the business of 22nd Century Ltd. the Company�� drug application for X-22 was cleared by the United States Food and Drug Administration (FDA) in July 2011. The Company�� subsidiary, Goodrich Tobacco Company, LLC (Goodrich Tobacco), had introduced two cigarette brands, RED SUN and MAGIC, into the United States marketed during the year ended December 31, 2011. In December 2013, 22nd Century Group Inc acquired an undisclosed manufacturing facility located in Mocksville, North Carolina. Effective December 11, 2013, 22nd Century Group Inc acquired NASCO Specialty Brands LLC.
X-22 is a tobacco-based botanical medical product for use as a smoking cessation therapy. X-22 is a prescription-only kit consists of very low nicotine (VLN) cigarettes made from its tobacco. The therapy protocol allows the patient to smoke its VLN cigarettes without restriction over the six-week treatment period to facilitate the goal of the patient quitting smoking by the end of the treatment period. In 2011, Biotech Crops were planted in 29 countries on 395 million acres (160 million hectares).
The Company competes with Pfizer Inc., GlaxoSmithKline PLC, Novartis International AG, Reynolds American Inc, Philip Morris USA Inc., Reynolds American Inc., Lorillard Inc., Commonwealth Brands, Inc., Liggett Group LLC, Vector Tobacco Inc., Star Scientific Inc, Philip Morris International Inc., British! American Tobacco, JT International SA, Imperial Tobacco Group PLC and China National Tobacco Corporation.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Chromadex Corp (OTCMKTS: CDXC) and 22nd Century Group Inc (OTCBB: XXII) are, one way or the other, focused on natural products and have been getting some extra attention lately. Moreover, one of these stocks have been the subject of a disclosed investor awareness campaign. Keeping that in mind, are these two small cap stocks natural winners for investors? Here is a quick look:
- [By James E. Brumley]
While it's only been a little over a week since yours truly named 22nd Century Group Inc. (NYSEMKT:XXII) as one of the market's best-looking breakout opportunities, circumstances dictate the message rather than the other way around. That's the indirect way of saying XXII has continued on ahead, behaving as expected, punching through its key ceilings and solidifying the bullishness it was hinting at late last month.
No comments:
Post a Comment